4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
RemeGen Co., Ltd. (9995) operates in the Biotechnology industry and is headquartered in Yantai, China with about 3,048 employees. Its market capitalization is roughly CNY 51 billion. In the fiscal year ended 2025-12-31, 9995 reported CNY 3.2B in revenue and CNY 710M in net income.
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | CNY 3.2B | CNY 1.7B | CNY 1.1B | CNY 768M | — |
| Gross Profit | CNY 2.8B | CNY 1.4B | CNY 823M | CNY 498M | — |
| Operating Income (EBIT) | CNY 156M | (CNY 1.4B) | (CNY 1.5B) | (CNY 1.1B) | — |
| Net Income | CNY 710M | (CNY 1.5B) | (CNY 1.5B) | (CNY 999M) | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | CNY 7.2B | CNY 5.5B | CNY 5.5B | CNY 6.0B | — |
| Total Liabilities | CNY 3.6B | CNY 3.5B | CNY 2.1B | CNY 1.0B | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 9995 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms